APhA’s Menighan Testifies on Increased Drug Prices

Thomas E. Menighan, Executive Director and CEO of the American Pharmacists Association, offered one specific remedy for increased drug prices to the Senate Senate’s Health, Education, Labor and Pensions (HELP) Committee.  Menighan urged the Senate to pass S109, the Pharmacy and Medically Underserved Areas Enhancement Act, which would amend the Social Security Act to provide Medicare coverage for pharmacist services.

Menighan also took a firm position on pharmaceutical rebates; under questioning from Senator Alexander, who asked “Why do we need rebates at all? Wouldn’t it increase transparency if manufacturers created a list price? Wouldn’t it make it simpler for us to figure out where the money goes?” Menighan said that his organization opposes rebates “in all their forms.” Additionally, Menighan reiterated APhA’s position against legalizing the importation of non-FDA approved drugs, saying that pharmacists shouldn’t have to worry about diversion and counterfeits and that ultimately the practice would do more harm than good.  APhA is a NCPIE member represented on the NCPIE Board of Directors.

http://www.pharmacist.com/article/apha-s-menighan-testifies-senate-drug-pricing